Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
777.60
+5.73 (0.74%)
Jan 2, 2026, 10:53 AM EST - Market open
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.75B in the quarter ending September 30, 2025, with 0.90% growth. This brings the company's revenue in the last twelve months to $14.25B, up 2.89% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.25B
Revenue Growth
+2.89%
P/S Ratio
5.73
Revenue / Employee
$943,188
Employees
15,106
Market Cap
79.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
| Dec 31, 2018 | 5.15B | -726.60M | -12.37% |
| Dec 31, 2017 | 5.87B | 1.01B | 20.82% |
| Dec 31, 2016 | 4.86B | 756.67M | 18.44% |
| Dec 31, 2015 | 4.10B | 1.28B | 45.55% |
| Dec 31, 2014 | 2.82B | 714.81M | 33.96% |
| Dec 31, 2013 | 2.10B | 726.27M | 52.69% |
| Dec 31, 2012 | 1.38B | 932.65M | 209.20% |
| Dec 31, 2011 | 445.82M | -13.25M | -2.89% |
| Dec 31, 2010 | 459.07M | 79.81M | 21.04% |
| Dec 31, 2009 | 379.27M | 140.81M | 59.05% |
| Dec 31, 2008 | 238.46M | 113.43M | 90.73% |
| Dec 31, 2007 | 125.02M | 61.58M | 97.05% |
| Dec 31, 2006 | 63.45M | -2.75M | -4.15% |
| Dec 31, 2005 | 66.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
REGN News
- 10 days ago - Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma - GlobeNewsWire
- 10 days ago - Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma - GlobeNewsWire
- 10 days ago - Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 13 days ago - Regeneron: The Turnaround Is Gaining Steam - Seeking Alpha
- 22 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Discusses Lynozyfic Development Strategy and Pipeline Opportunities in Multiple Myeloma Transcript - Seeking Alpha
- 22 days ago - Health Rounds: Regeneron drug wipes out residual multiple myeloma cells in small trial - Reuters
- 24 days ago - Regeneron Pharmaceuticals: Is Wall Street Finally Paying Attention? - Seeking Alpha
- 25 days ago - Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment - GlobeNewsWire